美国早期声门癌放疗分割方案与计划方法的经济影响
该研究基于美国监测、流行病学和最终结果数据库估算每年约3794例早期声门癌患者接受放疗,并按2019年Medicare定价分析费用。
要点
- 大分割放疗可降低费用9%至14%,而IMRT增加费用65%至72%。
- 基于3D的大分割放疗是当前标准治疗,支持支付方考虑循证报销政策。
核心结论
- 基于3D的大分割放疗是早期声门癌当前的标准治疗。
- 公共和私人支付方考虑基于证据的放疗报销政策是合理的。
研究设计与样本
- 基于美国监测、流行病学和最终结果数据库的群体分析,估算每年接受放疗的早期声门癌患者数。
- 放疗费用基于2019年Medicare定价,按分割方案和计划方法计算每例费用及总费用。
主要发现
- 估计每年有3794例早期声门癌患者接受放疗。
- 大分割放疗降低费用9%至14%,IMRT增加费用65%至72%。
关键数值与推荐
- 大分割放疗费用降低幅度:9%至14%。
- IMRT费用增加幅度:65%至72%。
临床怎么用
- 临床选择放疗方案时需权衡大分割的费用优势与IMRT的费用增加。
- 支付方可参考费用差异制定基于证据的放疗报销政策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early glottic cancers are often treated with radiotherapy (RT). We assessed the economic impact of fractionation scheme and planning method for payers in the United States. METHODS: A population-based analysis of the total cost of RT for early glottic cancers in the United States was performed annually. The target population was calculated using the Surveillance, Epidemiology, and End Results database. RT costs were based on 2019 pricing by Medicare. RESULTS: We estimate that 3794 patients with early glottic cancers are treated with RT annually. The cost of RT per patient ranges between US $13 964 and $26 599 by fractionation and planning method. Hypofractionation reduces costs by 9% to 14%, while Intensity-modulated radiotherapy (IMRT) increases costs by 65% to 72%. IMRT-based standard fractionation leads to an excess cost of $47 937 076 compared with 3D-based hypofractionation. CONCLUSIONS: 3D-based hypofractionated RT is the current standard of care. It would be reasonable for public and private payers to consider evidence-based policies for radiation reimbursement.
引用
- Moore A, Den RB, Popovtzer A, et al. Fractionation scheme and treatment planning method for early glottic cancer in the United States: Economic impact of different medical decisions. Head Neck. 2020. PMID: 31976607. doi:10.1002/hed.26082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。